Dr Chen completed his postdoctoral training at the University of Utah and has over 20 years of work experience in the pharmaceutical industry. He has extensive experience in new drug research, discovery, and clinical development for indications such as osteoporosis, osteoarthritis, metastatic bone disease and oncology.
He used to be a Senior Scientist in the R&D Department at the headquarters of Merck & Co., Inc. During his 10-year tenure, he was mainly responsible for the clinical trials (Phase I and Phase III) of project products Odanacatib and MK-0764. To date, the drug Odanacatib completed Phase II trials for the treatment of metastatic bone disease (MBD) in 2008 and Phase III clinical trials for the treatment of osteoporosis in 2016; the drug MK-0764 completed Phase III clinical trials for the treatment of osteoarthritis in 2017. He has published a total of 4 papers on the research results of these projects in journals including <JBMR>, <Bone>, and <Bone Report>.
Dr Chen has also participated in the preparation of WMA (World Market Application) documents for the Odanacatib product, making significant contributions to the registration of Odanacatib in multiple countries.
Ph.D. from the University of Louisville, USA, completed postdoctoral training at Yale University, USA, and earned an EMBA from Peking University.
With a strong background in medicinal chemistry, specializing in small molecule and peptide therapeutics.
Over 25 years of R&D and management experience in the biopharmaceutical industry, including more than 10 years as a founding CEO. Founded several biotech companies such as Keshine Pharmaceuticals and Suntech Biologics. Well-versed in capital markets, with hands-on experience leading a company to a successful IPO on the Nasdaq.
Responsible R&D, corporate management, financing, and business development (BD).
Dr. Jiang earned his Ph.D. in Medicinal Chemistry from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, followed by postdoctoral training at Oregon Health & Science University (OHSU) in the U.S. and served as a Visiting Professor at the University of California, Davis (UC Davis). He has been recognized as a Shanghai Oriental Talent (Leading Talent) and is a recipient of the Shanghai Talent Development Fund.
Dr Nancy E. Lane is the Leader of the Regenerative Medicine R&D Team in the United States, an Elected Member of the National Academy of Medicine (USA), and one of the key inventors of the novel drug LLP2A-Ale (RAB001). Internationally renowned, Dr. Lane is a preeminent scientist in the fields of osteoporosis and osteoarthritis.
Dr. Lane previously chaired the Board of Directors of the U.S. Bone and Joint Decade Initiative (now known as the Decade of Bone and Joint Initiative). She is an Elected Member of the American Association for the Advancement of Science (AAAS) Council and has held leadership positions within the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS). Dr. Lane also serves as Associate Editor for *Nature Reviews Rheumatology* and *Seminars in Arthritis and Rheumatism*, and as an Editorial Board Member of *The Journal of Rheumatology*.
Her distinctions include being an Elected Member of the Association of American Physicians (AAP) and the Institute of Medicine (IOM) of the National Academies (now part of the National Academy of Medicine). She has been consistently recognized as one of America's Top Doctors® annually since 2004 in the specialty of Rheumatology.
